News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS) Cannibalizes Gleevec to Boost New Cancer Drug


10/26/2012 6:03:45 AM

Novartis | Jobs at Novartis Pharmaceuticals

Novartis AG, the Swiss company revolutionized leukemia treatment with Gleevec, a drug that turned a deadly blood cancer into a chronic disease more than a decade ago. Many doctors have since come to believe that the drug, typically taken for life, may heal some patients for good, allowing treatment to be discontinued. The findings highlight one of the company’s biggest challenges: Gleevec, which generated $4.7 billion last year, loses patent protection and sales in 2014.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES